These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6110182)

  • 1. [Field trial with a new betablocker (Solgol)].
    Piergies A; Schimert G
    MMW Munch Med Wochenschr; 1980 Oct; 122(42):1473-6. PubMed ID: 6110182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of the beta-blocker nadolol on the second messenger, serum cyclic adenosine monophosphate, and on blood pressure and heart rate].
    Weth G; Schneider J; Rodatz H; Haubitz I
    Arzneimittelforschung; 1985; 35(11):1711-3. PubMed ID: 2868733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadolol, a once daily treatment for hypertension: multi-centre clinical evaluation.
    Jackson DA
    Br J Clin Pract; 1980 Jul; 34(7):211-21. PubMed ID: 6107120
    [No Abstract]   [Full Text] [Related]  

  • 4. Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
    Pupita F; Ansuini R; Belogi M; Pupita G; Gaggi S
    Int J Clin Pharmacol Res; 1985; 5(6):439-45. PubMed ID: 2869001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial therapy of essential hypertension: diuretic or beta blocker?
    Finnerty FA
    J Fam Pract; 1980 Aug; 11(2):199-205. PubMed ID: 6106039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Field study: long-term antihypertensive therapy with the beta blocker nadolol in a once-a-day dosage - an outpatient study of Swiss medical practices].
    Bertel O; Conen D; Renggli I
    Schweiz Rundsch Med Prax; 1983 Feb; 72(8):264-8. PubMed ID: 6132374
    [No Abstract]   [Full Text] [Related]  

  • 7. Bucindolol in essential hypertension.
    Reid JL; Curzio J; Vincent J
    Int J Clin Pharmacol Res; 1985; 5(5):293-301. PubMed ID: 2866166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lowering the heart rate in tachycardiac atrial fibrillation by beta receptor blockade].
    Horn HG; Neuss H; Schlepper M; Mitrovic V; Stämmler G
    Med Klin; 1980 Sep; 75(20):721-5. PubMed ID: 6106885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of the beta-blockers nadolol and metipranolol in patients with thyrotoxicosis].
    Vavrejnová V; Felt V; Nedvídková J
    Cas Lek Cesk; 1985 Oct; 124(43):1320-3. PubMed ID: 2867827
    [No Abstract]   [Full Text] [Related]  

  • 10. Nadolol (corgard) in severe and resistant hypertension.
    Nontak MA
    Med J Malaysia; 1981 Sep; 36(3):181-5. PubMed ID: 6120443
    [No Abstract]   [Full Text] [Related]  

  • 11. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
    Leenen FH; Davies RA; Fourney A
    Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metoprolol, a new cardioselective beta blocking agent in the treatment of arterial hypertension].
    Pedersen OL
    Ugeskr Laeger; 1975 Sep; 137(39):2274-6. PubMed ID: 241148
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute effects of metoprolol on blood pressure and heart rate. Value of the nitroglycerin test].
    Chaignon M; Lucsko M; Aubert P; Guédon J
    Arch Mal Coeur Vaiss; 1982 Sep; 75(9):963-9. PubMed ID: 6128964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of essential hypertension. A comparison between nadolol, once daily, and propranolol, four times daily.
    Frithz G
    Practitioner; 1982 Mar; 226(1365):562-4. PubMed ID: 7045847
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of hypotensive effect of nadolol].
    Cybulska I; Brym E; Czerniewska E; Wołyńczyk-Niegowska J
    Pol Arch Med Wewn; 1980 Dec; 64(6):475-80. PubMed ID: 6111065
    [No Abstract]   [Full Text] [Related]  

  • 18. A long-term evaluation of nadolol, a long-acting beta-adrenergic blocking agent, in the management of hypertension in general practice.
    O'Callaghan EG
    Br J Clin Pract; 1982 Jun; 36(6):235-9. PubMed ID: 6128994
    [No Abstract]   [Full Text] [Related]  

  • 19. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol.
    Mancia G; Ferrari A; Pomidossi G; Parati G; Bertinieri G; Grassi G; Gregorini L; di Rienzo M; Zanchetti A
    Am Heart J; 1984 Oct; 108(4 Pt 2):1078-83. PubMed ID: 6148866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.